The U.S. Food and Drug Administration (FDA) has cleared StimRouter, an implantable neuromodulation device designed to treat chronic, intractable pain of peripheral nerve origin from.
The device was developed by Bioness, a manufacturer of unique innovative systems for rehabilitation of impairments resulting from central nervous system disorders. The StimRouter is the only implanted device to be cleared by the FDA with a specific indication for peripheral nerve stimulation.
Fracture of Knee Cap
Patella fracture is a kneecap injury that needs surgical correction. Undisplaced fracture can be healed by using a brace to keep the knee immobile.
Advertisement
Bioness founder Alfred Mann said that StimRouter is a disruptive technology that presents an opportunity to change the way healthcare professionals treat chronic peripheral pain by targeting and neuromodulating the affected nerve.
"The device represents a less invasive and more cost-effective treatment method when compared to commercially available pain management implanted devices," Mann said.
![First of Its Kind Program Pioneered in Toronto Aims to Break the Chronic Pain Cycle]( "First of Its Kind Program Pioneered in Toronto Aims to Break the Chronic Pain Cycle")
Researchers are pioneering a world-first transitional pain program that aims to stop pain from becoming chronic after surgery.
Bioness President and CEO Todd Cushman said that the FDA clearance of StimRouter represents a monumental development for Bioness.
"The StimRouter builds on the success of our external neuromodulation systems and allows us to expand into the pain management market as well as other future applications. The positive clinical results, ease of use and a specific indication for use that targets peripheral nerve pain, make the StimRouter a unique and compelling alternative to Spinal Cord Stimulation (SCS) and opiates," Cushman said.
Source: Medindia
First of Its Kind Program Pioneered in Toronto Aims to Break the Chronic Pain Cycle
Researchers are pioneering a world-first transitional pain program that aims to stop pain from becoming chronic after surgery.
Advertisement
Bioness President and CEO Todd Cushman said that the FDA clearance of StimRouter represents a monumental development for Bioness.
"The StimRouter builds on the success of our external neuromodulation systems and allows us to expand into the pain management market as well as other future applications. The positive clinical results, ease of use and a specific indication for use that targets peripheral nerve pain, make the StimRouter a unique and compelling alternative to Spinal Cord Stimulation (SCS) and opiates," Cushman said.
Source: Medindia
People With Chronic Pain React to Painful Words
People who are suffering from chronic pain were more likely to pay attention to words that relate to pain.
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Medical Gadgets
The Apple Watch monitors heart rate, VO2 Max (oxygen intake during exercise), and ECG, warning users globally of cardiac abnormalities.
Apart from monitoring basic health, the new apple watch series 9 features a new double tap gesture to control apps without touching the watch.
Our artificial olfactory system combines sensing and processing efficiently, mirroring the biological olfactory system's function for energy and space savings.
A portable, lightweight, and affordable exoskeleton designed for stroke patients promises expanded accessibility, particularly in areas with limited resources.
A textile-based wearable device that 'taps' a user's wrist with pressurized air, silently guides the person finding their way to their destination.
